{"nctId":"NCT00265083","briefTitle":"A Study of the Safety and Efficacy of Golimumab in Subjects With Active Ankylosing Spondylitis","startDateStruct":{"date":"2005-12"},"conditions":["Spondylitis, Ankylosing"],"count":356,"armGroups":[{"label":"003","type":"EXPERIMENTAL","interventionNames":["Biological: golimumab"]},{"label":"001","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Golimumab (CNTO 148); placebo"]},{"label":"002","type":"EXPERIMENTAL","interventionNames":["Biological: golimumab"]}],"interventions":[{"name":"golimumab","otherNames":[]},{"name":"Golimumab (CNTO 148); placebo","otherNames":[]},{"name":"golimumab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of \"Definite AS\" (arthritis of the spine) as defined by the modified New York criteria, for at least 3 months prior to first dose of study drug\n* Symptoms of active disease at screening and at baseline visits, as evidenced by both a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of \\>= 4, and a Total Back Pain score of \\>= 4 (each on a scale of 0 to 10cm)\n* Inadequate response to 3 months of continuous therapy with maximal recommended doses of NSAIDs, or else unable to receive a full 3 months of maximal NSAID therapy because of intolerance, toxicity, or contraindications to non-steroidal anti-inflammatory drugs (NSAIDs)\n* Stable doses of methotrexate, sulfasalazine, hydroxychloroquine, low-dose corticosteroids, and NSAIDs are permitted.\n\nExclusion Criteria:\n\n* Patients cannot have complete ankylosis of the spine\n* No prior treatment with biologic anti-TNF agents (infliximab, etanercept, adalimumab)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Assessment in Ankylosing Spondylitis 20 Responders at Week 14","description":"Number of patients who achieved a 20% improvement and at least 1 absolute improvement on a 0 to 10 cm scale from baseline to Week 14 in at least 3 of the 4 domains: patient global, total back pain, function or inflammation.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"84","spread":null},{"groupId":"OG003","value":"166","spread":null}]}]}]},{"type":"SECONDARY","title":"Assessment in Ankylosing Spondylitis 20 Responders at Week 24","description":"Number of patients who achieved a 20% improvement and at least 1 absolute improvement on a 0 to 10 cm scale from baseline to Week 24 at least 3 of the 4 domains: patient global, total back pain, function or inflammation.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"77","spread":null},{"groupId":"OG002","value":"92","spread":null},{"groupId":"OG003","value":"169","spread":null}]}]}]},{"type":"SECONDARY","title":"Summary of Change From Baseline in Bath Ankylosing Spondylitis Functional Index at Week 14","description":"The Bath Ankylosing Spondylitis Functional Index (BASFI) is calculated as the mean of 10 VAS, each of length 0 to 10 cm. Eight of the scales relate to functional capacity of patients while the other 2 relate to a patient's ability to cope with everyday life. Change from baseline is Wk 14 value minus baseline value.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.095","spread":null},{"groupId":"OG001","value":"-1.375","spread":null},{"groupId":"OG002","value":"-1.495","spread":null},{"groupId":"OG003","value":"-1.420","spread":null}]}]}]},{"type":"SECONDARY","title":"Summary of Change From Baseline in Bath Ankylosing Spondylitis Metrology Index at Week 14","description":"The Bath Ankylosing Spondylitis Metrology Index (BASMI) is the sum of scores comprised of 5 measures (0=mild, 1=moderate \\& 2=severe): Tragus-to-wall; Lumbar flexion; Cervical rotation; Lumbar side flexion; Intermalleolar distance. BASMI ranges from 0 to 10. Change from baseline is Wk 14 value minus baseline value.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.28","spread":"1.015"},{"groupId":"OG001","value":"-0.36","spread":"1.112"},{"groupId":"OG002","value":"-0.49","spread":"1.296"},{"groupId":"OG003","value":"-0.43","spread":"1.208"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":27,"n":158},"commonTop":["Upper Respiratory Tract Infection","Nasopharyngitis","Arthralgia","Back Pain","Headache"]}}}